Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723359 · ClinicalTrials.gov registry record · Phase 1
Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Biotest Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00723359: Completed Phase 1 study, sponsored by Biotest Pharmaceuticals Corporation.
NCT00723359 is a Phase 1 study that has completed, run by Biotest Pharmaceuticals Corporation. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723359, a Phase 1 study, has completed, sponsored by Biotest Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
Interventions
- DRUG BT062
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT00723359 record still lists
NCT00723359 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which BT062 is the first listed.
NCT00723359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00723359 about?
NCT00723359 is a clinical study titled "Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma". This Phase I research study is to test the effects (good and bad) and best dose of BT062 in treating patients with relapsed or refractory multiple myeloma.
What is the current status of trial NCT00723359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00723359?
The interventions under investigation include: BT062 (DRUG).
Who is sponsoring clinical trial NCT00723359?
This trial is sponsored by Biotest Pharmaceuticals Corporation, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00723359's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia